{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06311578",
            "orgStudyIdInfo": {
                "id": "87704916LUC1001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-506495-27-00",
                    "type": "REGISTRY",
                    "domain": "EUCT number"
                }
            ],
            "organization": {
                "fullName": "Johnson & Johnson Enterprise Innovation Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors",
            "officialTitle": "Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-jnj-as-monotherapy-and-in-combination-for-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-11-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2033-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-08",
            "studyFirstSubmitQcDate": "2024-03-08",
            "studyFirstPostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Johnson & Johnson Enterprise Innovation Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 66,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with advanced solid tumors will receive JNJ-87704916 alone and in combination with cetrelimab. Ascending dose levels will be sequentially tested.",
                    "interventionNames": [
                        "Drug: JNJ-87704916",
                        "Drug: Cetrelimab"
                    ]
                },
                {
                    "label": "Part 2 Cohort A: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with relapsed/refractory metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1. Additional cohorts may be added to evaluate additional disease indications, or treatment regimens.",
                    "interventionNames": [
                        "Drug: JNJ-87704916",
                        "Drug: Cetrelimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "JNJ-87704916",
                    "description": "JNJ-87704916 will be administered as an intratumoral injection.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation",
                        "Part 2 Cohort A: Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetrelimab",
                    "description": "Cetrelimab will be administered.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation",
                        "Part 2 Cohort A: Dose Expansion"
                    ],
                    "otherNames": [
                        "JNJ-63723283"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)",
                    "description": "The DLTs are specific adverse events and are defined as any of the following: non-hematological toxicity and hematologic toxicity.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Number of Participants with Adverse Events (AEs) by Severity",
                    "description": "An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening, and Grade 5: death related to adverse event.",
                    "timeFrame": "From first dose up to 100 days after last dose of study treatment (up to 5 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Parts 1 and 2: Percentage of Participants With Objective Response (OR)",
                    "description": "OR is defined as the percentage of participants who have best response of Complete Response (CR) or Partial Response (PR) according to response evaluation criteria in solid tumors (RECIST) v1.1.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Parts 1 and 2: Percentage of Participants With Disease Control (DC)",
                    "description": "DC is defined as the percentage of participants who have achieved complete response, partial response, and stable disease according to RECIST v1.1.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Parts 1 and 2: Duration of Response (DOR)",
                    "description": "DOR will be calculated among responders from the date of initial documentation of a response to the date of first documented evidence of relapse according to RECIST v1.1, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Part 2: Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from treatment initiation until disease progression or worsening or death due to any cause.",
                    "timeFrame": "From treatment initiation until disease progression or worsening or death due to any cause (up to 5 years)"
                },
                {
                    "measure": "Part 2: Overall Survival (OS)",
                    "description": "OS is defined as the time from treatment initiation until death due to any cause.",
                    "timeFrame": "From treatment initiation until death due to any cause (up to 5 years)"
                },
                {
                    "measure": "Parts 1 and 2: Number of JNJ-87704916 Genome Copies per Milliliter",
                    "description": "Viral genome copies of JNJ-87704916 collected from samples (that is, blood, urine, oral mucosa, injection sites, and dressings) will be determined by quantitative polymerase chain reaction (qPCR) assays.",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Parts 1 and 2: Payload Concentrations of JNJ-87704916",
                    "description": "Blood samples will be collected to characterize JNJ-87704916 payload concentrations in blood and tumor and will be analyzed using immunoassay.",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Parts 1 and 2: Number of Participants with JNJ-87704916 Antibodies",
                    "description": "Antibodies against JNJ-87704916 encoded payloads and against herpes simplex virus type-1 (HSV-1) will be analyzed.",
                    "timeFrame": "Up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy\n* Have at least 1 injectable tumor\n* Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1\n* A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study\n\nExclusion Criteria:\n\n* Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed\n* Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy\n* Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents\n* History of solid organ or hematologic stem cell transplantation\n* Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Johnson & Johnson Enterprise Innovation Inc Clinical Trial",
                    "affiliation": "Johnson & Johnson Enterprise Innovation Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UPMC Cancer Centers",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Hosp Univ Fund Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hosp Univ Hm Sanchinarro",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",
            "url": "https://www.janssen.com/clinical-trials/transparency"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}